Predictive Oncology, Inc.

How big is Predictive Oncology, Inc.?

As of Jun 18, Predictive Oncology, Inc. has a market capitalization of 8.22 million, with recent net sales of 1.35 million and a net profit of -9.85 million. The company's shareholder's funds were -0.20 million, and total assets amounted to 4.97 million.

Market Cap: As of Jun 18, Predictive Oncology, Inc. has a market capitalization of 8.22 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1.35 million and a net profit of -9.85 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -0.20 million, and total assets amounted to 4.97 million.

What does Predictive Oncology, Inc. do?

Predictive Oncology, Inc. utilizes artificial intelligence for personalized medicine and drug discovery in the Pharmaceuticals & Biotechnology sector. As of March 2025, it has a market cap of $8.22 million, with net sales of $0 million and a net profit of -$2 million.

Overview: <BR>Predictive Oncology, Inc. is focused on applying artificial intelligence (AI) to personalized medicine and drug discovery within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 8.22 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 2.57 <BR>Return on Equity: 985.13% <BR>Price to Book: -8.22<BR><BR>Contact Details: <BR>Address: 2915 Commers Dr Ste 900, EAGAN MN: 55121-2363 <BR>Tel: 1 651 3894800 <BR>Website: http://www.precisiontherapeutics.com

Should I buy, sell or hold Predictive Oncology, Inc.?

Who are in the management team of Predictive Oncology, Inc.?

As of March 2022, the management team of Predictive Oncology, Inc. includes Dr. Carl Schwartz as President and CEO, along with Directors Mr. J. Engle, Mr. H. Gabriel, Dr. Daniel Handley, Ricardo Koenigsberger, and Mr. Timothy Krochuk.

As of March 2022, the management team of Predictive Oncology, Inc. includes Dr. Carl Schwartz, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors consists of Mr. J. Engle, Mr. H. Gabriel, Dr. Daniel Handley, Ricardo Koenigsberger, and Mr. Timothy Krochuk, all of whom hold the position of Director.

Is Predictive Oncology, Inc. overvalued or undervalued?

As of August 14, 2018, Predictive Oncology, Inc. is considered overvalued and risky due to negative valuation ratios and a significant long-term decline of 94.26%, despite a recent year-to-date stock return of 20.39%.

As of 14 August 2018, the valuation grade for Predictive Oncology, Inc. moved from does not qualify to risky, indicating heightened concerns regarding its financial health. The company appears to be overvalued based on its negative valuation ratios, including a Price to Book Value of -8.38, an EV to EBIT of -0.59, and an EV to EBITDA of -0.61. These figures suggest significant challenges in generating positive returns relative to its capital structure.<BR><BR>In comparison to its peers, Predictive Oncology's valuation ratios are notably weaker; for instance, Nutriband, Inc. has a much higher EV to EBITDA of -11.2912, while Nephros, Inc. boasts a strong P/E ratio of 31.3944, highlighting the disparity in financial performance within the sector. Despite a recent positive stock return of 20.39% year-to-date, which outperformed the S&P 500's 12.22%, the long-term performance remains concerning, with a staggering decline of 94.26% over five years. This combination of negative ratios and poor long-term performance reinforces the conclusion that Predictive Oncology, Inc. is overvalued.

Is Predictive Oncology, Inc. technically bullish or bearish?

As of September 8, 2025, Predictive Oncology, Inc. shows a neutral technical trend with mixed signals, mildly bullish indicators on MACD and KST, but underperformance against the S&P 500 over longer periods despite recent short-term gains.

As of 8 September 2025, the technical trend for Predictive Oncology, Inc. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the KST also shows mild bullishness in the same periods. However, the daily moving averages indicate a mildly bearish stance. The Bollinger Bands present a bullish signal weekly but are mildly bearish monthly. The Dow Theory shows no trend on a weekly basis but is mildly bullish monthly. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 3.92% and 15.71% compared to 1.05% and 2.33% for the index, respectively. However, over longer periods, the stock has significantly underperformed the S&P 500, particularly over the 3-year and 5-year periods.